Furthermore, synthetic selective inhibitors of CRM1 with pharmacological properties superior to LMB (selinexor/KPT‐330), which have shown to be well‐tolerated in human cancer clinical trials (Mahipal & Malafa, 2016), would facilitate future in vivo evaluation of this therapy in HGPS animal models. Here, XPO1 is linked to cancer.